CY1119610T1 - Φαρμακευτικη συνθεση που περιλαμβανει (1r,4r)-6'-φθορο-ν,ν-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3'h-σπιρο[κυκλοεξαν-1,1'-πυρανο'[3,4,b]ινδολ]-4-αμινη παρακεταμολη ή προπακεταμολη - Google Patents

Φαρμακευτικη συνθεση που περιλαμβανει (1r,4r)-6'-φθορο-ν,ν-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3'h-σπιρο[κυκλοεξαν-1,1'-πυρανο'[3,4,b]ινδολ]-4-αμινη παρακεταμολη ή προπακεταμολη

Info

Publication number
CY1119610T1
CY1119610T1 CY20171101212T CY171101212T CY1119610T1 CY 1119610 T1 CY1119610 T1 CY 1119610T1 CY 20171101212 T CY20171101212 T CY 20171101212T CY 171101212 T CY171101212 T CY 171101212T CY 1119610 T1 CY1119610 T1 CY 1119610T1
Authority
CY
Cyprus
Prior art keywords
fluoro
dimethyl
amine
phenyl
pharmaceutical composition
Prior art date
Application number
CY20171101212T
Other languages
English (en)
Inventor
Stefanie Frosch
Klaus Linz
Klaus Schiene
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1119610T1 publication Critical patent/CY1119610T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση αφορά μια φαρμακευτική σύνθεση, η οποία περιέχει ένα πρώτο φαρμακολογικώς δραστικό συστατικό, το οποίο επιλέγεται από (1r,4r)-6'-φθορο-Ν,Ν-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3'H-σπιρο[κυκλοεξαν-1,1'-πυρανο[3,4,b]ινδολ]-4-αμίνη και τα φυσιολογικώς αποδεκτά άλατα αυτής, και ένα δεύτερο φαρμακολογικώς δραστικό συστατικό, το οποίο επιλέγεται από παρακεταμόλη και προπακεταμόλη.
CY20171101212T 2012-05-18 2017-11-20 Φαρμακευτικη συνθεση που περιλαμβανει (1r,4r)-6'-φθορο-ν,ν-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3'h-σπιρο[κυκλοεξαν-1,1'-πυρανο'[3,4,b]ινδολ]-4-αμινη παρακεταμολη ή προπακεταμολη CY1119610T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12003897 2012-05-18
PCT/EP2013/001468 WO2013170969A1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano'[3,4,b]indol]-4-amine and paracetamol or propacetamol
EP13723674.1A EP2849740B1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano'[3,4,b]indol]-4-amine and paracetamol or propacetamol

Publications (1)

Publication Number Publication Date
CY1119610T1 true CY1119610T1 (el) 2018-04-04

Family

ID=48468208

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101212T CY1119610T1 (el) 2012-05-18 2017-11-20 Φαρμακευτικη συνθεση που περιλαμβανει (1r,4r)-6'-φθορο-ν,ν-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3'h-σπιρο[κυκλοεξαν-1,1'-πυρανο'[3,4,b]ινδολ]-4-αμινη παρακεταμολη ή προπακεταμολη

Country Status (23)

Country Link
US (3) US20130310435A1 (el)
EP (1) EP2849740B1 (el)
JP (1) JP6116676B2 (el)
CN (2) CN108524498A (el)
AU (1) AU2013262075B2 (el)
BR (1) BR112014028561A2 (el)
CA (1) CA2873644A1 (el)
CY (1) CY1119610T1 (el)
DK (1) DK2849740T3 (el)
EA (1) EA026949B1 (el)
ES (1) ES2650441T3 (el)
HK (1) HK1204940A1 (el)
HR (1) HRP20171438T1 (el)
HU (1) HUE034676T2 (el)
IL (1) IL235651B (el)
LT (1) LT2849740T (el)
MX (1) MX352596B (el)
NO (1) NO2849740T3 (el)
PL (1) PL2849740T3 (el)
PT (1) PT2849740T (el)
RS (1) RS56617B1 (el)
SI (1) SI2849740T1 (el)
WO (1) WO2013170969A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017009416A (es) 2015-01-23 2017-10-12 Gruenenthal Gmbh Cebranopadol para tratar el dolor en sujetos con insuficiencia hepatica o renal.

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068838B1 (en) 1981-06-26 1986-09-17 The Upjohn Company Analgesic process and composition
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4404208A (en) 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and tiflamizole
IE55189B1 (en) 1982-07-08 1990-06-20 Wyeth John & Brother Ltd Pharmaceutical compositions
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
ATE46265T1 (de) 1985-01-23 1989-09-15 Asta Pharma Ag Synergistische kombination von flupirtin und nicht-steroidalen antiphlogistika.
EP0473655B1 (en) 1989-05-22 1997-01-15 Biochemical Veterinary Research Pty. Ltd. Divalent metal salts of indomethacin
CA2112378A1 (en) 1991-07-04 1993-01-21 Masakazu Kanazawa Analgesic preparation
JPH05221857A (ja) * 1992-02-14 1993-08-31 Arakusu:Kk 配合解熱鎮痛剤
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
AU680020B2 (en) 1993-06-07 1997-07-17 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
ES2190241T3 (es) 1998-09-10 2003-07-16 Nycomed Danmark As Compuestos farmaceuticos de liberacion rapida de substancias medicamentosas.
EP1135121B1 (en) 1998-11-13 2003-03-12 Eli Lilly And Company Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain
DE50104197D1 (de) 2000-12-28 2004-11-25 Fresenius Kabi Austria Gmbh Gr Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung
MXPA04007242A (es) 2002-01-28 2004-10-29 Pfizer Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1.
EP1374906B1 (en) 2002-06-17 2007-04-18 CHIESI FARMACEUTICI S.p.A. A process for the preparation of piroxicam: beta-cyclodextrin inclusion compounds
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10257824B4 (de) 2002-12-10 2004-11-11 Kochem, Hans-Günter, Dr. Zusammensetzung zur Schmerzbehandlung, insbesondere zur Behandlung von Gelenkschmerzen
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US7132452B2 (en) 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2006257274A1 (en) 2005-06-17 2006-12-21 Pfizer Inc. Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as ORL1-receptor antagonists
CN105561311B (zh) 2006-04-28 2019-07-16 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
DE602007011913D1 (de) 2006-04-28 2011-02-24 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
CN101147735A (zh) * 2006-09-19 2008-03-26 沈阳华泰药物研究有限公司 注射用药物组合物及其药盒
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102006056458A1 (de) * 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
EP2207569B1 (en) 2007-10-09 2013-03-27 Merck Patent GmbH Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
CN100560061C (zh) 2008-06-20 2009-11-18 海南锦瑞制药股份有限公司 一种氯诺昔康冻干粉针剂及其制备方法
BRPI0918566A2 (pt) * 2008-09-05 2016-02-10 Gruenenthal Gmbh combinacao farmacêutica compreendendo 6-dimetilanometil-1-(3-metóxifenil)-ciclo-hexano-1,3-diol e paracetamol
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
EP2331102A1 (en) 2008-09-05 2011-06-15 Grünenthal GmbH Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and an nsaid
BR112013002696A2 (pt) * 2010-08-04 2016-05-31 Gruenenthal Gmbh forma de dosagem farmacêutica compreendendo 6'-fluor-(n-metil- ou n,n-dimetil-)4-fenil-4',9'-diidro-3'h-espiro[cicloexano-1,-1'-pirano[3,4-b]indol]-4 amina 13''
CN103260610A (zh) * 2010-08-04 2013-08-21 格吕伦塔尔有限公司 治疗伤害性疼痛的含6’-氟-(N-甲基-或N,N-二甲基-)-4-苯基-4’,9’-二氢-3’H-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺的药物剂型
ES2553742T3 (es) * 2010-08-04 2015-12-11 Grünenthal GmbH Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative

Also Published As

Publication number Publication date
DK2849740T3 (da) 2017-11-20
US20130310435A1 (en) 2013-11-21
EA201401272A1 (ru) 2015-05-29
EP2849740A1 (en) 2015-03-25
PT2849740T (pt) 2017-12-13
RS56617B1 (sr) 2018-02-28
AU2013262075A1 (en) 2015-01-22
US20190350884A1 (en) 2019-11-21
JP6116676B2 (ja) 2017-04-19
CA2873644A1 (en) 2013-11-21
HK1204940A1 (en) 2015-12-11
CN104302282A (zh) 2015-01-21
MX352596B (es) 2017-11-30
MX2014012723A (es) 2015-01-15
CN108524498A (zh) 2018-09-14
NO2849740T3 (el) 2018-02-10
EA026949B1 (ru) 2017-06-30
EP2849740B1 (en) 2017-09-13
LT2849740T (lt) 2017-12-27
WO2013170969A1 (en) 2013-11-21
BR112014028561A2 (pt) 2017-07-25
PL2849740T3 (pl) 2018-03-30
US20180092867A1 (en) 2018-04-05
IL235651B (en) 2018-08-30
US11311504B2 (en) 2022-04-26
IL235651A0 (en) 2015-01-29
HUE034676T2 (hu) 2018-02-28
ES2650441T3 (es) 2018-01-18
HRP20171438T1 (hr) 2017-11-03
JP2015516449A (ja) 2015-06-11
AU2013262075B2 (en) 2017-10-26
SI2849740T1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
ECSP13012423A (es) FORMA DE DOSIFICACION FARMACEUTICA QUE COMPRENDE 6'-FLUORO-(N-METIL- O N,N-DIMETIL)-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA PARA EL TRATAMIENTO DE DOLOR NEUROPATICO
CO6640316A2 (es) Forma de dosificación famaceutica que comprende 6´fluoro-(n-metil-o n,n.dimetil)-4-fenil-4´9-dhidro-3 h espiro[ciclohexan-1´1-pirano[3.4,b[indol]-4-amina
CL2012003583A1 (es) Forma de dosificacion farmaceutica para administracion dos veces al dia, una vez al dia o con menos frecuencia, que contiene 6’-fluoro-(n-metil- o n,n-dimetil-)-4-fenil-4’,9’-dihidro-3’h-espiro[ciclohexan –1,1’-pirano[3,4,b]indol]-4-amina y un tensioactivo,
EA201500857A1 (ru) Комбинированные вакцины с синтетическими наноносителями
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
CY1120525T1 (el) Κρυσταλλικη (1r,4r)-6'-φθορο-ν,ν-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3'h-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,b]ινδολ]-4-αμινη
CY1119777T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα (1r,4r)-6'-φθοpo-n,n-διμεθυλ-4-φαινυλ-4',9'διυδρο-3'h-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,β]ινδολ]-4-αμινη και γκαμπαπεντινοειδες
BR112014028571A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6'-fluoro-n , n-dimetil-4' ,9-di-hidro-3'h-espiro[ciclo-hexano-1 ,1'-pirano-[3,4,b]indol]-4-amina e um derivado de ácido propiónico .
CY1119887T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΗ ΜΟΡΦΗ ΔΟΣΟΛΟΓΙΑΣ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 6'-ΦΘΟΡΟ-(Ν-ΜΕΘΥΛΟ- Ή Ν,Ν-ΔΙΜΕΘΥΛΟ-)-4-ΦΑΙΝΥΛΟ-4',9'-ΔΙΥΔΡΟ-3'Η-ΣΠΕΙΡΟ [ΚΥΚΛΟΕΞΑΝΟ-1,1'-ΠΥΡΑΝΟ[3,4,b] ΙΝΔΟΛ]-4-ΑΜΙΝΗ
CY1119610T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει (1r,4r)-6'-φθορο-ν,ν-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3'h-σπιρο[κυκλοεξαν-1,1'-πυρανο'[3,4,b]ινδολ]-4-αμινη παρακεταμολη ή προπακεταμολη
CY1119781T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει (1r,4r)-6'-φθοpo-n,n-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3'h-σπειρο[κυκλοεξανο-1,1'-πυρανο-[3,4,β]ινδολ]-4-αμινη και ιμπουπροφενη
CY1118132T1 (el) ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ (1R,4R)-6'-ΦΘΟΡΟ-Ν,Ν-ΔΙΜΕΘΥΛ-4-ΦΑΙΝΥΛ-4',9'-ΔΙΥΔΡΟ-3´H-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1'-ΠΥΡΑΝΟ[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ
CY1119825T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα (1r,4r)-6'-φθopo-n,n-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3'h-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,β]ινδολ]-4-αμινη και ντουλοξετινη
CY1119692T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει (1r,4r)-6'-φθορο-ν,ν-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3ή-σπιρο [κυκλο-εξανο-1,1'-πυρανο-(3,4,b)ινδολ)-αμινη και ακετυλο-σαλικυλικο οξυ
CY1118799T1 (el) (1r,4r)-6’-φθopo-(n-meθyλ- ή ν,ν-διμεθυλ-)-4-φαινυλ-4’,9’-διϋδρο-3’h-σπειρο-[κυκλοεξανο-1,1’πυρανο[3,4,β]ινδολ]-4-αμινη για θεραπεια ινομυαλγιας και συνδρομου χρονιας κοπωσεως
BR112014028569A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n , n-dimetil-4 ,9-di-hidro-3h-espiro[ciclo-hexano-1 ,1-pirano-[3,4,b]indol]-4-amina e um oxicam
CY1116996T1 (el) Φαρμακευτικη δοσολογικη μορφη που περιεχει 6'-φθορο-(ν-μεθυλο- ή ν,ν-διμεθυλο-)-4-φαινυλο-4',9',-διυδρο-3'η-σπιρο[κυκλοεξαν-1,1'-πυρανο[3,4-β]ινδολ]-4-αμινη
CY1117385T1 (el) Φαρμακευτικη μορφη δοσολογιας περιλαμβανουσα 6'-φθορο-(ν-μεθυλ-ή ν,ν-διμεθυλ-)-4-φαινυλ-4΄,9'-διϋδρο-3ή-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,β]ινδολ]-4-αμινη
BR112014028557A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n ,n-dimetil-4-fenil-4 ,9-di-hidro-3h-espiro[ciclohexano-1 ,1-pirano-[3,4,b]indol]-4- amina e um anticonvulsivo